Browse > Article
http://dx.doi.org/10.5483/BMBRep.2011.44.4.232

Current progress on development of respiratory syncytial virus vaccine  

Chang, Jun (College of Pharmacy, and Division of Life & Pharmaceutical Sciences, Ewha Womans University)
Publication Information
BMB Reports / v.44, no.4, 2011 , pp. 232-237 More about this Journal
Abstract
Human respiratory syncytial virus (HRSV) is a major cause of upper and lower respiratory tract illness in infants and young children worldwide. Despite its importance as a respiratory pathogen, there is currently no licensed vaccine for prophylaxis of HRSV infection. There are several hurdles complicating the development of a RSV vaccine: 1) incomplete immunity to natural RSV infection leading to frequent re-infection, 2) immature immune system and maternal antibodies of newborn infants who are the primary subject population, and 3) imbalanced Th2-biased immune responses to certain vaccine candidates leading to exacerbated pulmonary disease. After the failure of an initial trial featuring formalin-inactivated virus as a RSV vaccine, more careful and deliberate efforts have been made towards the development of safe and effective RSV vaccines without vaccine-enhanced disease. A wide array of RSV vaccine strategies is being developed, including live-attenuated viruses, protein subunit-based, and vector-based candidates. Though licensed vaccines remain to be developed, our great efforts will lead us to reach the goal of attaining safe and effective RSV vaccines in the near future.
Keywords
Pathogenesis; Protection; Respiratory syncytial virus; Vaccine; Vaccine strategy;
Citations & Related Records

Times Cited By Web Of Science : 2  (Related Records In Web of Science)
Times Cited By SCOPUS : 3
연도 인용수 순위
1 Bembridge, G. P., Rodriguez, N., Garcia-Beato, R., Nicolson, C., Melero, J. A. and Taylor, G. (2000) Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine 19, 1038-1046.   DOI   ScienceOn
2 Groothuis, J. R., King, S. J., Hogerman, D. A., Paradiso, P. R. and Simoes, E. A. (1998) Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J. Infect. Dis. 177, 467-469.   DOI   ScienceOn
3 de Waal, L., Power, U. F., Yuksel, S., van Amerongen, G., Nguyen, T. N., Niesters, H. G., de Swart, R. L. and Osterhaus, A. D. (2004) Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine 22, 915-922.   DOI   ScienceOn
4 Power, U. F., Nguyen, T. N., Rietveld, E., de Swart, R. L., Groen, J., Osterhaus, A. D., de Groot, R., Corvaia, N., Beck, A., Bouveret-Le-Cam, N. and Bonnefoy, J. Y. (2001) Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J. Infect Dis. 184, 1456-1460.   DOI   ScienceOn
5 Kohlmann, R., Schwannecke, S., Tippler, B., Ternette, N., Temchura, V. V., Tenbusch, M., Uberla, K. and Grunwald, T. (2009) Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J. Virol. 83, 12601- 12610.   DOI   ScienceOn
6 Yu, J. R., Kim, S., Lee, J. B. and Chang, J. (2008) Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J. Virol. 82, 2350-2357.   DOI   ScienceOn
7 Hsu, K. H., Lubeck, M. D., Davis, A. R., Bhat, R. A., Selling, B. H., Bhat, B. M., Mizutani, S., Murphy, B. R., Collins, P. L., Chanock, R. M. and Hung, P. P. (1992) Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. J. Infect Dis. 166, 769-775.   DOI   ScienceOn
8 Takimoto, T., Hurwitz, J. L., Zhan, X., Krishnamurthy, S., Prouser, C., Brown, B., Coleclough, C., Boyd, K., Scroggs, R. A., Portner, A. and Slobod, K. S. (2005) Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral. Immunol. 18, 255-266.   DOI   ScienceOn
9 Murphy, B. R., Sotnikov, A. V., Lawrence, L. A., Banks, S. M. and Prince, G. A. (1990) Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8, 497-502.   DOI   ScienceOn
10 Murphy, B. R., Sotnikov, A., Paradiso, P. R., Hildreth, S. W., Jenson, A. B., Baggs, R. B., Lawrence, L., Zubak, J. J., Chanock, R. M., Beeler, J. A. and Prince, G. A. (1989) Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7, 533-540.   DOI   ScienceOn
11 Prince, G. A., Denamur, F., Deschamps, M., Garcon, N., Prieels, J. P., Slaoui, M., Thiriart, C. and Porter, D. D. (2001) Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine 19, 2048-2054.   DOI   ScienceOn
12 Hancock, G. E., Heers, K. M., Pryharski, K. S., Smith, J. D. and Tiberio, L. (2003) Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus. Vaccine 21, 4348-4358.   DOI   ScienceOn
13 Hancock, G. E., Speelman, D. J., Heers, K., Bortell, E., Smith, J. and Cosco, C. (1996) Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol. 70, 7783-7791.
14 Wright, P. F., Karron, R. A., Belshe, R. B., Thompson, J., Crowe, J. E. Jr., Boyce, T. G., Halburnt, L. L., Reed, G. W., Whitehead, S. S., Anderson, E. L., Wittek, A. E., Casey, R., Eichelberger, M., Thumar, B., Randolph, V. B., Udem, S. A., Chanock, R. M. and Murphy, B. R. (2000) Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182, 1331-1342.   DOI   ScienceOn
15 Karron, R. A., Wright, P. F., Belshe, R. B., Thumar, B., Casey, R., Newman, F., Polack, F. P., Randolph, V. B., Deatly, A., Hackell, J., Gruber, W., Murphy, B. R. and Collins, P. L. (2005) Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191, 1093-1104.   DOI   ScienceOn
16 Wright, P. F., Karron, R. A., Madhi, S. A., Treanor, J. J., King, J. C., O'Shea, A., Ikizler, M. R., Zhu, Y., Collins, P. L., Cutland, C., Randolph, V. B., Deatly, A. M., Hackell, J. G., Gruber, W. C. and Murphy, B. R. (2006) The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J. Infect Dis. 193, 573-581.   DOI   ScienceOn
17 Tebbey, P. W., Hagen, M. and Hancock, G. E. (1998) Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J. Exp. Med. 188, 1967-1972.   DOI
18 Johnson, T. R., Varga, S. M., Braciale, T. J. and Graham, B. S. (2004) Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin- inactivated RSV. J. Virol. 78, 8753-8760.   DOI   ScienceOn
19 Openshaw, P. J., Clarke, S. L. and Record, F. M. (1992) Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4, 493-500.   DOI   ScienceOn
20 Nicholas, J. A., Rubino, K. L., Levely, M. E., Adams, E. G. and Collins, P. L. (1990) Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. J. Virol. 64, 4232-4241.
21 Heidema, J., de Bree, G. J., De Graaff, P. M., van Maren, W. W., Hoogerhout, P., Out, T. A., Kimpen, J. L. and van Bleek, G. M. (2004) Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J. Gen. Virol. 85, 2365-2374.   DOI   ScienceOn
22 Johnson, T. R., Johnson, J. E., Roberts, S. R., Wertz, G. W., Parker, R. A. and Graham, B. S. (1998) Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J. Virol. 72, 2871-2880.
23 De Swart, R. L., Kuiken, T., Timmerman, H. H., van Amerongen, G., Van Den Hoogen, B. G., Vos, H. W., Neijens, H. J., Andeweg, A. C. and Osterhaus, A. D. (2002) Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J. Virol. 76, 11561-11569.   DOI
24 Connors, M., Giese, N. A., Kulkarni, A. B., Firestone, C. Y., Morse, H. C. 3rd and Murphy, B. R. (1994) Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin- 4 (IL-4) and IL-10. J. Virol. 68, 5321-5325.
25 Levine, S., Klaiber-Franco, R., and Paradiso, P. R. (1987) Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J. Gen. Virol. 68(Pt 9), 2521-2524.   DOI   ScienceOn
26 Bastien, N., Trudel, M. and Simard, C. (1999) Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines. Vaccine 17, 832-836.   DOI   ScienceOn
27 Taylor, G., Stott, E. J., Bew, M., Fernie, B. F., Cote, P. J., Collins, A. P., Hughes, M. and Jebbett, J. (1984) Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52, 137-142.
28 Sparer, T. E., Matthews, S., Hussell, T., Rae, A. J., Garcia- Barreno, B., Melero, J. A. and Openshaw, P. J. (1998) Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187, 1921-1926.   DOI
29 Martinez, I. and Melero, J. A. (1998) Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein. J. Gen. Virol. 79(Pt 9), 2215-2220.   DOI
30 Johnson, P. R., Spriggs, M. K., Olmsted, R. A. and Collins, P. L. (1987) The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc. Natl. Acad. Sci. U.S.A. 84, 5625-5629.   DOI
31 Johnson, S., Oliver, C., Prince, G. A., Hemming, V. G., Pfarr, D. S., Wang, S. C., Dormitzer, M., O'Grady, J., Koenig, S., Tamura, J. K., Woods, R., Bansal, G., Couchenour, D., Tsao, E., Hall, W. C. and Young, J. F. (1997) Development of a humanized monoclonal antibody (MEDI- 493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect Dis. 176, 1215-1224.   DOI   ScienceOn
32 Graham, B. S., Bunton, L. A., Wright, P. F. and Karzon, D. T. (1991) Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Invest. 88, 1026-1033.   DOI
33 Waris, M. E., Tsou, C., Erdman, D. D., Zaki, S. R. and Anderson, L. J. (1996) Respiratory synctial virus infection in BALB/c mice previously immunized with formalininactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70, 2852-2860.
34 Alwan, W. H., Record, F. M. and Openshaw, P. J. (1992) CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. Clin. Exp. Immunol. 88, 527-536.
35 Kapikian, A. Z., Mitchell, R. H., Chanock, R. M., Shvedoff, R. A. and Stewart, C. E. (1969) An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89, 405-421.   DOI
36 Murphy, B. R. and Walsh, E. E. (1988) Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion- inhibiting activity. J. Clin. Microbiol. 26, 1595-1597.
37 Mok, H., Lee, S., Utley, T. J., Shepherd, B. E., Polosukhin, V. V., Collier, M. L., Davis, N. L., Johnston, R. E. and Crowe, J. E. Jr. (2007) Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J. Virol. 81, 13710-13722.   DOI   ScienceOn
38 Li, X., Sambhara, S., Li, C. X., Ewasyshyn, M., Parrington, M., Caterini, J., James, O., Cates, G., Du, R. P. and Klein, M. (1998) Protection against respiratory syncytial virus infection by DNA immunization. J. Exp. Med. 188, 681-688.   DOI
39 Schmidt, A. C., McAuliffe, J. M., Murphy, B. R. and Collins, P. L. (2001) Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J. Virol. 75, 4594-4603.   DOI   ScienceOn
40 Elliott, M. B., Chen, T., Terio, N. B., Chong, S. Y., Abdullah, R., Luckay, A., Egan, M. A., Boutilier, L. A., Melville, K., Lerch, R. A., Long, D., Eldridge, J. H., Parks, C. L., Udem, S. A. and Hancock, G. E. (2007) Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine 25, 7132-7144.   DOI   ScienceOn
41 Cano, F., Plotnicky-Gilquin, H., Nguyen, T. N., Liljeqvist, S., Samuelson, P., Bonnefoy, J., Stahl, S. and Robert, A. (2000) Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides. Vaccine 18, 2743-2752.   DOI   ScienceOn
42 Martinez-Sobrido, L., Gitiban, N., Fernandez-Sesma, A., Cros, J., Mertz, S. E., Jewell, N. A., Hammond, S., Flano, E., Durbin, R. K., Garcia-Sastre, A. and Durbin, J. E. (2006) Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J. Virol. 80, 1130-1139.   DOI   ScienceOn
43 Bukreyev, A., Yang, L., Fricke, J., Cheng, L., Ward, J. M., Murphy, B. R. and Collins, P. L. (2008) The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor- bearing leukocytes. J. Virol. 82, 12191-12204.   DOI   ScienceOn
44 Hall, C. B., Walsh, E. E., Long, C. E. and Schnabel, K. C. (1991) Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect Dis. 163, 693-698.   DOI   ScienceOn
45 Walsh, E. E., Hall, C. B., Briselli, M., Brandriss, M. W. and Schlesinger, J. J. (1987) Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J. Infect Dis. 155, 1198-1204.   DOI   ScienceOn
46 Connors, M., Collins, P. L., Firestone, C. Y. and Murphy, B. R. (1991) Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65, 1634-1637.
47 Piedra, P. A., Cron, S. G., Jewell, A., Hamblett, N., McBride, R., Palacio, M. A., Ginsberg, R., Oermann, C. M. and Hiatt, P. W. (2003) Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 21, 2448-2460.   DOI   ScienceOn
48 Tristram, D. A., Welliver, R. C., Mohar, C. K., Hogerman, D. A., Hildreth, S. W. and Paradiso, P. (1993) Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J. Infect. Dis. 167, 191-195.   DOI   ScienceOn
49 Chang, J. and Braciale, T. J. (2002) Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract. Nat. Med. 8, 54-60.   DOI   ScienceOn
50 Schlender, J., Walliser, G., Fricke, J. and Conzelmann, K. K. (2002) Respiratory syncytial virus fusion protein mediates inhibition of mitogen-induced T-cell proliferation by contact. J. Virol. 76, 1163-1170.   DOI
51 Pringle, C. R., Filipiuk, A. H., Robinson, B. S., Watt, P. J., Higgins, P. and Tyrrell, D. A. (1993) Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 11, 473-478.   DOI   ScienceOn
52 Henderson, F. W., Collier, A. M., Clyde, W. A. Jr. and Denny, F. W. (1979) Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N. Engl. J. Med. 300, 530-534.   DOI   ScienceOn
53 Johnson, T. R., Teng, M. N., Collins, P. L. and Graham, B. S. (2004) Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J. Virol. 78, 6024-6032.   DOI   ScienceOn
54 Crowe, J. E. Jr., Firestone, C. Y. and Murphy, B. R. (2001) Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J. Immunol. 167, 3910-3918.   DOI
55 Glezen, W. P., Taber, L. H., Frank, A. L. and Kasel, J. A. (1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140, 543-546.
56 Srikiatkhachorn, A. and Braciale, T. J. (1997) Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186, 421-432.   DOI
57 Martinez, I., Dopazo, J. and Melero, J. A. (1997) Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J. Gen. Virol. 78(Pt 10), 2419-2429.   DOI
58 Connors, M., Kulkarni, A. B., Collins, P. L., Firestone, C. Y., Holmes, K. L., Morse, H. C. 3rd and Murphy, B. R. (1992) Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J. Virol. 66, 1277-1281.